Table 1 Clinical, metabolic, and inflammatory variables characterizing the cardiovascular risk profile in the whole sample at baseline and after 1 year
Baseline (n = 137) | Follow-up (n = 105) | p value | |
|---|---|---|---|
CV risk factors | |||
BMI, kg/m2 | 25.08 ± 3.88 | 25.09 ± 3.98 | N.s. |
Smoke, (%) | 40 | 39 | N.s. |
Hypertension, (%) | 48.6 | 54.2 | 0.045 |
Dyslipidaemia, (%) | 68.6 | 67.6 | N.s. |
Diabetes, (%) | 6.7 | 6.7 | N.s. |
Systolic BP (mmHg) | 136.5 ± 17.7 | 134.9 ± 16.4 | N.s. |
Diastolic BP (mmHg) | 83.4 ± 9.1 | 81.1 ± 9.7 | N.s. |
Fasting glycaemia, mg/dl | 90.96 ± 24.59 | 89.88 ± 22.01 | N.s. |
Total cholesterol, mg/dl | 215.15 ± 38.08 | 209.14 ± 46.00 | N.s. |
LDL, mg/dl | 120.28 ± 33.97 | 120.17 ± 35.36 | N.s. |
HDL, mg/dl | 69.52 ± 18.92 | 69.34 ± 18.58 | N.s. |
Triglycerides, mg/dl | 121.88 ± 61.85 | 113.86 ± 55.22 | N.s. |
RA characteristics | |||
CRP, mg/l | 4.19 ± 8.43 | 3.96 ± 6.61 | N.s. |
DAS28 [CRP] | 2.65 ± 1.08 | 2.77 ± 1.33 | N.s. |
Disease duration at baseline, years | 15.45 ± 10.57 | – | – |
RA treatments | |||
csDMARDs, % | 76.6 | 72.9 | N.s. |
Methotrexate, % | 53.3 | 45.8 | – |
Leflunomide, % | 17.8 | 18.7 | – |
Hydroxychloroquine, % | 12.1 | 11.2 | – |
bDMARDs, % | 74.8 | 70.1 | N.s. |
TNFi, % | 45.8 | 40.2 | – |
Tocilizumab, % | 11.2 | 11.2 | – |
Rituximab, % | 5.6 | 4.7 | – |
Abatacept, % | 9.3 | 13.1 | – |
Corticosteroids, % | 66.4 | 57.9 | 0.028 |
NSAIDs, % | 20.6 | 21.5 | N.s. |
